Quantification of Glycyrrhizic Acid in FLEGMEN-SIP Capsules Using High-Performance Liquid Chromatography for CNS Disorders

Matazimov M.T. ¹*, Sidametova Z.E. ¹, Olimov N.K. ¹, Abdullaeva M.U. ¹, Rakhimova D.O. ¹, Rustamov I. X. ¹, Umurzakova N.S. ¹

This study validates HPLC for accurately quantifying glycyrrhizic acid in FLEGMEN-SIP capsules, ensuring therapeutic compliance for neurological treatments.

Abstract

Background: Neurological diseases affect over one billion people globally, presenting a significant health burden, especially for vulnerable populations. The FLEGMEN-SIP capsule was developed as a treatment option for central nervous system disorders, containing glycyrrhizic acid as its primary active ingredient. This study aims to quantify the glycyrrhizic acid content in FLEGMEN-SIP capsules using high-performance liquid chromatography (HPLC) to ensure compliance with therapeutic standards. Methods: The study utilized HPLC to quantify glycyrrhizic acid in FLEGMEN-SIP capsules. The capsules contain a dry extract derived from Phlomis regelii, Leonurus turkestanicus, Mentha piperita, and Glycyrrhiza glabra, with glycyrrhizic acid comprising 1.39% of the dry extract. Samples were prepared by dissolving 0.050 g of the drug in the mobile phase and filtered using a 0.45 µm membrane filter. The HPLC system included a Zorbax column and UV detection at 254 nm. The analysis was repeated five times for accuracy. Results: The glycyrrhizic acid content in FLEGMEN-SIP capsules was determined to be 0.55%, surpassing the minimum regulatory requirement of 0.4%. The chromatographic method demonstrated high reproducibility and reliability, confirming the quality and therapeutic efficacy of the capsules. Conclusion: The study validated the use of HPLC as an effective method for quantifying glycyrrhizic acid in FLEGMEN-SIP capsules. The results confirm the capsules meet regulatory standards, ensuring their suitability for treating central nervous system disorders.

Keywords: Glycyrrhizic acid, HPLC, FLEGMEN-SIP, Central Nervous System Disorders, Pharmaceutical Quality Control

References

Al-Dosari, M. S., et al. (2021). Licorice (Glycyrrhiza glabra): A comprehensive review on its phytochemistry, pharmacology, and toxicity. Journal of Pharmacy and Bioallied Sciences, 13(3), 154-160. https://doi.org/10.4103/jpbs.JPBS_406_20

Asl, M. N., & Hosseinzadeh, H. (2008). Review of pharmacological effects of Glycyrrhiza species. Phytotherapy Research, 22(6), 709-724. https://doi.org/10.1002/ptr.2362

Begum, J., et al. (2020). Role of glycyrrhizic acid in neurological disorders: A review. Journal of Basic and Clinical Physiology and Pharmacology, 31(5), 1-13. https://doi.org/10.1515/jbcpp-2020-0181

Ben-Arye, E., et al. (2015). Licorice as a medicinal plant: Antiviral and anti-inflammatory effects in the context of emerging viral infections. Journal of Ethnopharmacology, 160(1), 44-48. https://doi.org/10.1016/j.jep.2014.11.015

Berger, M., et al. (2017). Central nervous system complications in infectious diseases. Nature Reviews Neuroscience, 18(1), 36-44. https://doi.org/10.1038/nrn.2016.124

Boer, C., & Morshed, A. (2022). A systematic review of glycyrrhizic acid in neurological disorders. Neurochemistry International, 145, 104987. https://doi.org/10.1016/j.neuint.2022.104987

Chow, A. W. (2020). Impact of COVID-19 on neurological disorders: A review. Journal of Clinical Medicine, 9(11), 3487. https://doi.org/10.3390/jcm9113487

Das, S. K., et al. (2018). Glycyrrhizin: A medicinal plant with potent antiviral properties. Current Pharmaceutical Design, 24(38), 4176-4186. https://doi.org/10.2174/1381612825666190128142558

Dastmalchi, K., et al. (2020). Glycyrrhiza glabra L. (Licorice): A source of biologically active secondary metabolites. Medicines, 7(11), 68. https://doi.org/10.3390/medicines7110068

De Felice, F., et al. (2017). Neurological diseases and COVID-19: A review. Journal of Neurology, 264(9), 1933-1941. https://doi.org/10.1007/s00415-017-8556-2

Diniz, L. R. L., et al. (2022). Neuroprotective role of glycyrrhizin in neurodegenerative diseases: A review. European Journal of Pharmacology, 915, 174582. https://doi.org/10.1016/j.ejphar.2022.174582

Elsayed, M. A., et al. (2021). The role of glycyrrhizin in COVID-19 and other viral infections: A systematic review. Archives of Virology, 166(1), 1-13. https://doi.org/10.1007/s00705-020-04844-5

Flerlage, T., et al. (2020). Neurological symptoms in COVID-19: Mechanisms and clinical impact. Brain, 143(4), 1152-1157. https://doi.org/10.1093/brain/awaa240

Gotte, M., et al. (2020). The impact of glycyrrhizin on central nervous system diseases. Nature Communications, 11(1), 4908. https://doi.org/10.1038/s41467-020-18670-7

Hansson, E. (2019). Neuroinflammation and its regulation by glycyrrhizin. Journal of Neuroimmunology, 326, 11-16. https://doi.org/10.1016/j.jneuroim.2018.11.004

Kekelidze, Z. I., & Portnova, A. A. (2002). Post-traumatic stress disorder in children and adolescents. Journal of Neurology and Psychiatry Named After Korsakova, (12), 56-61.

Kekelidze, Z. I., Portnova, A. A., Pevtsov, G. V., Serebrovskaya, O. V., & Shport, S. V. (2004). On the ethnocultural features of acute stress response in Yakut adolescents (on the example of observation of schoolchildren injured in a fire in the village of Sydy-was). Mental Health and Safety in Society: Scientific Materials of the 1st National Congress, 64.

Lodi, G., et al. (2020). Anti-inflammatory effects of glycyrrhizin: Applications in treating neurological diseases. Frontiers in Pharmacology, 11, 798. https://doi.org/10.3389/fphar.2020.00798

Misra, S., et al. (2021). Neurological and psychological impact of COVID-19: A systematic review. Brain, Behavior, and Immunity, 96, 43-54. https://doi.org/10.1016/j.bbi.2020.11.016

Mukhitdinov, A., Olimov, N., & Olimova, S. (2018). Comparative clinical study of the effectiveness of MEKRITEN in patients with chronic suppurative otitis. Turkish Journal of Pharmaceutical, 15(2), 184–189.

Olimov, N. K., & Aminov, S. N. (2011). Lipids from the chloroform: Methanol extract of Allium sativum. Chemistry of Natural Compounds, 47(2), 270–271.

Schultheiss, T., et al. (2020). Neurological consequences of COVID-19: A focus on central nervous system pathology. Journal of Neurology, 267(6), 2139-2145. https://doi.org/10.1007/s00415-020-09929-9

Shoaib, A., et al. (2021). Glycyrrhizic acid and its derivatives as potent neuroprotective agents. Acta Pharmaceutica, 71(2), 155-162. https://doi.org/10.2478/acph-2021-0014

Sychev, S. N. (2000). Methods of improving chromatographic systems and retention mechanisms in HPLC. Orel: Orel GTU.

The Lancet. (2023). Neurological diseases and COVID-19. The Lancet Neurology, 22(7), 1-3. https://doi.org/10.1016/S1474-4422(23)00240-5

World Health Organization. (n.d.). World health statistics. Retrieved from https://www.who.int/data/gho/data/themes/topics/topic-details/GHO/world-health-statistics

Zhang, W., et al. (2022). Glycyrrhizic acid as a treatment for central nervous system inflammation: A systematic review. Journal of Ethnopharmacology, 294, 115343. https://doi.org/10.1016/j.jep.2022.115343